Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer - Cancer Currents Blog National Cancer Institute sent this bulletin at 07/05/2022 10:36 AM EDT The latest from the NCI Cancer Currents blog Having trouble viewing this email? View it as a Web page. You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below. Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer 07/05/2022 People with metastatic breast cancer whose tumors had low levels of HER2 protein lived longer after treatment with trastuzumab deruxtecan (Enhertu) than those treated with standard chemotherapy, results of the DESTINY-Breast04 clinical trial show.
